Flt3 ligand and conjugation to IL-1β peptide as adjuvants for a type 1, T-cell response to an HIV p17 gag vaccine

Vladimir M. Pisarev, Prahlad Parajuli, R Lee Mosley, Jennifer Chavez, Daniel Zimmerman, Douglas Winship, James E Talmadge

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The adjuvant activity of Flt3 ligand (Flt3L) and conjugation to an interleukin (IL)-1β bioactive fragment were compared, either alone or in combination, for their ability to induce T- and B-cell responses to the HGP-30 peptide sequence (amino acids 86-115 of human immunodeficiency virus (HIV) gag p17). The efficiency of HGP-30/IL-1β conjugation, Flt3L administration or both as adjuvants was examined and all were found to augment similar levels of delayed type hypersensitivity (DTH) responses. In contrast, significant antigen (Ag)-specific types 1 and 2 T-cell ELISPOT responses were induced only by the combination of adjuvants. Further, in vitro sensitization with HGP-30 selectively increased Ag-specific, type 1 T-cell and cytotoxic T lymphocyte (CTL) responses to HGP-30-derived nonapeptide epitopes, while type 2 responses declined as measured in the ELISPOT assay. No serum antibodies to HGP-30 were induced unless HGP-30 was conjugated to keyhole-limpet hemocyanin. This suggests that a combination adjuvant strategy using Flt3L and conjugation to a biologically active IL-1β fragment may be used to preferentially increase type 1 T-cell and CTL responses to HIV-1 gag antigenic epitopes.

Original languageEnglish (US)
Pages (from-to)2358-2368
Number of pages11
JournalVaccine
Volume20
Issue number17-18
DOIs
StatePublished - May 22 2002

Fingerprint

Human immunodeficiency virus
interleukin-1
Interleukin-1
adjuvants
Enzyme-Linked Immunospot Assay
Vaccines
T-lymphocytes
HIV
Cytotoxic T-Lymphocytes
peptides
vaccines
T-Lymphocytes
Peptides
cytotoxic T-lymphocytes
Epitopes
epitopes
Antigens
Delayed Hypersensitivity
antigens
delayed hypersensitivity

Keywords

  • Flt3 ligand
  • Gag
  • IL-1β fragment
  • Peptide conjugates
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Flt3 ligand and conjugation to IL-1β peptide as adjuvants for a type 1, T-cell response to an HIV p17 gag vaccine. / Pisarev, Vladimir M.; Parajuli, Prahlad; Mosley, R Lee; Chavez, Jennifer; Zimmerman, Daniel; Winship, Douglas; Talmadge, James E.

In: Vaccine, Vol. 20, No. 17-18, 22.05.2002, p. 2358-2368.

Research output: Contribution to journalArticle

Pisarev, Vladimir M. ; Parajuli, Prahlad ; Mosley, R Lee ; Chavez, Jennifer ; Zimmerman, Daniel ; Winship, Douglas ; Talmadge, James E. / Flt3 ligand and conjugation to IL-1β peptide as adjuvants for a type 1, T-cell response to an HIV p17 gag vaccine. In: Vaccine. 2002 ; Vol. 20, No. 17-18. pp. 2358-2368.
@article{90140b53f263488aa13beff71ead17b5,
title = "Flt3 ligand and conjugation to IL-1β peptide as adjuvants for a type 1, T-cell response to an HIV p17 gag vaccine",
abstract = "The adjuvant activity of Flt3 ligand (Flt3L) and conjugation to an interleukin (IL)-1β bioactive fragment were compared, either alone or in combination, for their ability to induce T- and B-cell responses to the HGP-30 peptide sequence (amino acids 86-115 of human immunodeficiency virus (HIV) gag p17). The efficiency of HGP-30/IL-1β conjugation, Flt3L administration or both as adjuvants was examined and all were found to augment similar levels of delayed type hypersensitivity (DTH) responses. In contrast, significant antigen (Ag)-specific types 1 and 2 T-cell ELISPOT responses were induced only by the combination of adjuvants. Further, in vitro sensitization with HGP-30 selectively increased Ag-specific, type 1 T-cell and cytotoxic T lymphocyte (CTL) responses to HGP-30-derived nonapeptide epitopes, while type 2 responses declined as measured in the ELISPOT assay. No serum antibodies to HGP-30 were induced unless HGP-30 was conjugated to keyhole-limpet hemocyanin. This suggests that a combination adjuvant strategy using Flt3L and conjugation to a biologically active IL-1β fragment may be used to preferentially increase type 1 T-cell and CTL responses to HIV-1 gag antigenic epitopes.",
keywords = "Flt3 ligand, Gag, IL-1β fragment, Peptide conjugates, Vaccine",
author = "Pisarev, {Vladimir M.} and Prahlad Parajuli and Mosley, {R Lee} and Jennifer Chavez and Daniel Zimmerman and Douglas Winship and Talmadge, {James E}",
year = "2002",
month = "5",
day = "22",
doi = "10.1016/S0264-410X(02)00096-8",
language = "English (US)",
volume = "20",
pages = "2358--2368",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "17-18",

}

TY - JOUR

T1 - Flt3 ligand and conjugation to IL-1β peptide as adjuvants for a type 1, T-cell response to an HIV p17 gag vaccine

AU - Pisarev, Vladimir M.

AU - Parajuli, Prahlad

AU - Mosley, R Lee

AU - Chavez, Jennifer

AU - Zimmerman, Daniel

AU - Winship, Douglas

AU - Talmadge, James E

PY - 2002/5/22

Y1 - 2002/5/22

N2 - The adjuvant activity of Flt3 ligand (Flt3L) and conjugation to an interleukin (IL)-1β bioactive fragment were compared, either alone or in combination, for their ability to induce T- and B-cell responses to the HGP-30 peptide sequence (amino acids 86-115 of human immunodeficiency virus (HIV) gag p17). The efficiency of HGP-30/IL-1β conjugation, Flt3L administration or both as adjuvants was examined and all were found to augment similar levels of delayed type hypersensitivity (DTH) responses. In contrast, significant antigen (Ag)-specific types 1 and 2 T-cell ELISPOT responses were induced only by the combination of adjuvants. Further, in vitro sensitization with HGP-30 selectively increased Ag-specific, type 1 T-cell and cytotoxic T lymphocyte (CTL) responses to HGP-30-derived nonapeptide epitopes, while type 2 responses declined as measured in the ELISPOT assay. No serum antibodies to HGP-30 were induced unless HGP-30 was conjugated to keyhole-limpet hemocyanin. This suggests that a combination adjuvant strategy using Flt3L and conjugation to a biologically active IL-1β fragment may be used to preferentially increase type 1 T-cell and CTL responses to HIV-1 gag antigenic epitopes.

AB - The adjuvant activity of Flt3 ligand (Flt3L) and conjugation to an interleukin (IL)-1β bioactive fragment were compared, either alone or in combination, for their ability to induce T- and B-cell responses to the HGP-30 peptide sequence (amino acids 86-115 of human immunodeficiency virus (HIV) gag p17). The efficiency of HGP-30/IL-1β conjugation, Flt3L administration or both as adjuvants was examined and all were found to augment similar levels of delayed type hypersensitivity (DTH) responses. In contrast, significant antigen (Ag)-specific types 1 and 2 T-cell ELISPOT responses were induced only by the combination of adjuvants. Further, in vitro sensitization with HGP-30 selectively increased Ag-specific, type 1 T-cell and cytotoxic T lymphocyte (CTL) responses to HGP-30-derived nonapeptide epitopes, while type 2 responses declined as measured in the ELISPOT assay. No serum antibodies to HGP-30 were induced unless HGP-30 was conjugated to keyhole-limpet hemocyanin. This suggests that a combination adjuvant strategy using Flt3L and conjugation to a biologically active IL-1β fragment may be used to preferentially increase type 1 T-cell and CTL responses to HIV-1 gag antigenic epitopes.

KW - Flt3 ligand

KW - Gag

KW - IL-1β fragment

KW - Peptide conjugates

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=0037157270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037157270&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(02)00096-8

DO - 10.1016/S0264-410X(02)00096-8

M3 - Article

C2 - 12009292

AN - SCOPUS:0037157270

VL - 20

SP - 2358

EP - 2368

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 17-18

ER -